FindTrial
Sign In

Retrospective Analysis of the Efficacy and Safety of Isavuconazole versus Other Antifungal Agents as First-Line Treatment for invasive mold disease in Patients with Hematologic Malignancies

Retrospective comparison of Isavuconazole (ISA) and other antifungal agents as first-line treatment of invasive mold disease in patients with hematological malignancies-A single center study on efficacy and safety in real-life clinical practice.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600122840
Enrollment
Unknown
Registered
2026-04-20
Start date
2022-01-01
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive Mold Disease

Interventions

Observation group:None

Sponsors

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.All patients who met the criteria for confirmed, clinically diagnosed, or suspected invasive fungal disease, as defined by the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria, were included in the study between January 2022 and August 2025.

Exclusion criteria

Exclusion criteria: 1. significant data missing. 2. severe hepatic or renal dysfunction.

Design outcomes

Primary

MeasureTime frame
Global Overall Response Rate;—

Secondary

MeasureTime frame
Survival Analysis (OS, PFS);Adverse Event Rates (Hepatotoxicity/Nephrotoxicity, QTc Prolongation, etc.);—

Countries

China

Contacts

Public ContactHaowen Xiao

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

haowenxiaoxiao@126.com+86 571 8600 6567

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026